Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: GlobalData
$125.00
Provider: Crystal Research Associates
$817.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarantus announces positive top-line interim clinical data for Alzheimer's Blood Diagnostic LymPro Test


Friday, 1 Aug 2014 09:25am EDT 

Amarantus Bioscience Holdings Inc:Announces positive interim clinical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test, currently under development for Alzheimer's disease diagnosis.Says in an interim analysis of 44 subjects (34 healthy controls and 10 Alzheimer's patients) from LP-002, a projected 72 patient clinical performance study.Announced it achieved replication of the two earlier peer reviewed publications, the primary objective of the study.The interim analysis completed from the blood samples drawn from the 44 subjects in the LP-002 clinical study was conducted with the primary objective to identify whether the Company could replicate data published in two peer-reviewed publications. 

Company Quote

0.079
0.0020 +2.60%
19 Dec 2014